Statin use may lower risk of Crohn's Disease: Study

Sweden: The use of statins is associated with a lower risk of Crohn's Disease but not of Ulcerative Colitis, according to a study published in the Journal of Crohn's and Colitis.

Inflammatory bowel disease (IBD) is a condition characterized by chronic inflammation of a part or the entire gastrointestinal tract. The most common types of IBD are Crohn's disease (CD) and ulcerative colitis (UC). It affects more than 6.8 million patients globally and is a cause for significant morbidity and economic burden on the health care system. Statins are potent lipid-lowering agents prescribed on a global scale for the primary and secondary prevention of cardiovascular disease and treatment of dyslipidemia. There is sufficient evidence to show that statin use may modulate inflammation. However, data associating statin use to IBD does not exist.

With this background, researchers from Sweden, led by Paul Lochhead, carried out a nationwide, population-based case-control study to examine the association between statin use and risk of IBD in a population. The Nationwide Swedish Patient Register [inpatient and non-primary outpatient care] was searched to identify adults diagnosed with Crohn's disease [CD, n = 7637] or ulcerative colitis [UC, n = 15 652] from 2006 to 2014. Each case was matched to 10 general population controls [n = 232 890]. Data on dispensed statin prescriptions were extracted from the Prescribed Drug Register. Odds ratios [ORs] were estimated using conditional logistic regression models, for risk of IBD according to statin exposure while controlling for potential confounders, including indications for statin therapy.